NCT05964790View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

July 30, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 30, 2024

Conditions
Schizophrenia
Interventions
DRUG

HS-10380

Participants in arm HS-10380 will receiving multiple ascending doses of HS-10380 (1.5 mg initial dose) orally once daily for 28 days

DRUG

Placebo

Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY